TargetMol

UR-13870

Product Code:
 
TAR-T29071
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T29071-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29071-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29071-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
UR-13870 is a p38 mitogen-activated protein kinase (MAPK) inhibitor.
CAS:
755753-89-0
Formula:
C24H16F2N4
Molecular Weight:
398.417
Purity:
0.98
SMILES:
Cn1cc2c(-c3ccc(F)cc3)c(-c3ccncc3)c(nc2n1)-c1ccc(F)cc1

References

1. Galan-Arriero I, Avila-Martin G, Ferrer-Donato A, Gomez-Soriano J, Bravo-Esteban E, Taylor J. Oral administration of the p38? MAPK inhibitor, UR13870, inhibits affective pain behavior after spinal cord injury. Pain. 2014 Oct;155(10):2188-98. doi: 10.1016/j.pain.2014.08.030. PubMed PMID: 25180015. 2. Galan-Arriero I, Avila-Martin G, Ferrer-Donato A, Gomez-Soriano J, Piazza S, Taylor J. Early treatment with UR13870, a novel inhibitor of p38? mitogenous activated protein kinase, prevents hyperreflexia and anxiety behaviors, in the spared nerve injury model of neuropathic pain. Neurosci Lett. 2015 Sep 14;604:69-74. doi: 10.1016/j.neulet.2015.07.044. PubMed PMID: 26240995. 3. Mihara K, Almansa C, Smeets RL, Loomans EE, Dulos J, Vink PM, Rooseboom M, Kreutzer H, Cavalcanti F, Boots AM, Nelissen RL. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha. Br J Pharmacol. 2008 May;154(1):153-64. doi: 10.1038/bjp.2008.53. PubMed PMID: 18297096; PubMed Central PMCID: PMC2438984.